COMPASS Pathways plc — Company profile
Healthcare · Medical Care Facilities · United Kingdom
Last price 12.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Details
| Name | COMPASS Pathways plc |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Employees | 156 |
| Founded | 2020 |
| Ipo Date | 2020-09-18 |
| Ceo | Kabir Nath |
| Country | United Kingdom |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US20451W1018 |
| Cusip | 20451W101 |
| Cik | 1816590 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer and Executive Director |
| Teri Loxam M.B.A. | Chief Financial Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Kelley Boucher | Chief People Officer |
| Lars Christian Wilde | Senior Advisor |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Dr. Michael Gold M.D., M.Sc. | Chief Research and Development Officer |
| Lori Englebert M.B.A. | Chief Commercial Officer |
| Dr. Steve Levine M.D. | Chief Patient Officer |
Contact
| Address | 33 Broadwick Street, London, W1F 0DQ, United Kingdom |
| Phone | 44 716 6766461 |
| Website | https://compasspathways.com |